ARTICLE | Politics, Policy & Law
In deciding mifepristone case, court could safeguard FDA from judicial second-guessing
By Steve Usdin, Washington Editor
March 27, 2024 11:18 PM UTC


The Supreme Court seems inclined to rebuff an attempt by anti-abortion activists to restrict access to the abortion drug mifepristone. How the court disposes of the case, especially the arguments it makes in overturning lower court decisions, will be critically important for biopharmaceutical companies and FDA.
The best outcome for the biopharma industry would be a clear ruling that the lower courts shouldn’t have considered the case in the first place because the plaintiffs lacked legal standing to sue FDA. This would shut the Pandora’s box that Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas opened in April 2023 when he ruled that physicians with remote and largely imaginary connections to the approval and regulation of mifepristone had standing to sue the agency…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651923/supreme-court-could-shut-lid-on-pandora-s-box-shielding-fda